In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier

Drug Metabolism and Disposition

Volumn 36, Issue 3, 2008, Pages 481-484

  Hsiao, Peng ^a   Bui, Tot ^a   Ho, Rodney J Y ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CLARITHROMYCIN; CYCLOSPORIN A; ERYTHROMYCIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; NELFINAVIR; QUINIDINE; QUININE; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VERAPAMIL;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG INHIBITION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOOD-BRAIN BARRIER; BORON COMPOUNDS; CARBAMATES; CARBON RADIOISOTOPES; CYCLOSPORINE; DRUG INTERACTIONS; FLUORESCENT DYES; HUMANS; LLC-PK1 CELLS; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; QUINIDINE; QUININE; RATS; SULFONAMIDES; SWINE; VERAPAMIL;

RATTUS; RODENTIA;

EID: 40849145621     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018176     Document Type: Article

References (11)

1. Bernareggi A and Rowland M (1991) Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 19:21-50.
2. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
3. Endres CJ, Hsiao P, Chung FS, and Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517.
4. Hendrikse NH and Vaalburg W (2002) Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography. Methods 27:228-233.
5. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, and Unadkat JD (2006) Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317:704-710.
6. Lin JH and Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454.
7. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, and Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
8. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
9. Sadeque AJ, Wandel C, He H, Shah S, and Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
10. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
11. Woodahl EL, Yang Z, Bui T, Shen DD, and Ho RJ (2004) Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 310:1199-1207.